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Prostate cancer (PC) affects elderly men more than young men. The currently 
used cancer biomarker, prostate-specific antigen (PSA), highly overestimates PC 
population. Men with high PSA levels often have to go through unnecessary, but 
physically painful, and expensive prosesses, such as prostate biopsies. Finding a prostate 
cancer marker that is produced selectively by cancer, but not by normal prostate cells will 
increase the reliability of PC test. In 2006, our collaborator (Dr. Girish Shah) discovered 
a novel protein, referred as neuroendocrine marker (NEM), secreted only by malignant 
prostate cells and released in blood circulation.
To examine whether the combined NEM-PSA test can improve the reliability for 
early PC detection, we have developed a nanoporous thin film sensor that can reliably 
detect PSA and NEM in patient samples. The thin film sensor is fabricated from 
nanoporous anodic aluminum oxide and uses an optical Fabry-Perot intereferometric 
technique. This optical sensor has been tested for several assay paradigms, including non­
specific binding, reliability, accuracy, precision, and sensitivity. The results demonstrate 
that the optical nanoporous thin film sensor is reliable and extremely sensitive when used 
with only 0.5 pi of patient serum (or even less) to measure levels of the PSA and NEM, 
even in a non-cancer individual. When compared with the traditional ELISA test for 
PSA, the nanosensor assay is several-fold more sensitive, and it elimnates the need for 
labeled antigen, sample processing, complex equipment, and highly experienced
iv
individuals. These benefits, along with the low cost, should make the technology suitable 
for Point-of-Care application to accurately screen elderly male populations for PC and to 
monitor the progress of patients undergoing PC treatment. Nanoporous thin-film sensor 
was able to detect prostate cancer markers concentrations as low as 1 pg/ml for NEM and 
20 pg/ml for PSA.
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1.1 Overview of Nanosensors for Biodetection
Technology is growing rapidly, and this affects our lifestyle. As a result, we need 
to keep pace with developments that accrued in our world. Biomedical engineering is an 
engineering field that concerns engineering methods such as electrical, optical, 
mechanical, and chemical to medical and biological applications [1].
Biomedical engineering has many aims and goals, such as to develop amended 
kinds of animals and plants for food manufacturing, to design new diagnostic tests 
methods for diseases, to improve drug release devices, to improve the safety and the 
efficiency of medical devices, to improve diagnostic imaging systems, to give better 
solutions for neuro system defects, as well as many other goals [1].
Also, Biomedical engineers are working on connecting new technologies to 
medical and biological fields in many ways like innovating new diagnostic and treatment 
methods and improving existing biosensing capabilities. Reliable solutions are needed to 
reduce the cost and the demand on the health care system and to minimize the number of 
deaths.
In general, biosensors consists of four major components (Figure 1-1) [2]. The 
first component is the analyte, which is a biological or chemical compound that will be
1
easured and/or monitored. The receptor is the second component of the biosensor. It has a 
crucial role in immobilizing the component that will be detected (analyte) over the sensor 
surface. To make sure that the sensor is accurate and reliable, the receptor should only 
bound to the analyte. Antigens, which can be defined as foreign substances that catalyze 
the body to produce antibodies [3], are examples of analytes. Antigens have a significant 




Figure 1-1. Schematic of biosensor four major components (analyte, receptor, transducer, 
and detector) [4].
Antibodies are an excellent example of bioreceptors. An antibody is a large 
protein that is generated by plasma cells. It has a Y-shape, with the two upper arms called 
fragment antigen binding (Fab) regions, which make contact with, and bind to, the 
antigen.
By knowing that each antibody antigen binding site (paratope) is specific to each 
antigen epitope, we can consider that the binding relation between paratope and epitope is 
like a lock-key relation. The antibody base region is called fragment crystallizable region 
(Fc), and its primary function is to make and provide an extra binding with the antigen.
Since enzymes have specific binding properties, they could also be used as a 
receptor for biosensing applications, especially for the DNA detection.
3
The transducer is the third component of the biosensor. It transforms signals from 
one form to another. For example, a Quartz Crystal Microbalance (QCM) device converts 
the pressure applied over a quartz surface into a change in frequency [5]. The fourth 
component of the biosensor is the detector, which is the part that identifies the stimulus 
[6].
Biological analytes are often small in size, ranging from a few nanometers to a 
few micrometers, and they are often low-weight. As a result, there is a significant need 
for sensors that can work at micro or nanoscale. Microscale and nanoscale biosensors 
include nanoparticle-based biosensors [7], acoustic wave biosensors [6], magneto­
nanosensor biosensors [8], electrochemical biosensors [9], carbon nanotube-based 
sensors [10], nanowire based sensors [11], surface enhanced Raman spectroscopy [12], 
and fluorescence and light scattering [13].
Biomolecules can be detected through two methods, attached to a tag or a label 
like epitope tags, radioisotopes, fluorescent dyes [14-16], or not attached to a tag (label- 
free). However, the labels could affect the properties of the analyte; they can be 
expensive or toxic and require a skilled person to work with them. On the other hand, 
label-free biosensing technique will reduce the cost of the experiment, and analyte 
specifications will not be affected since it has no connection to any external compound.
The label-free technologies are currently used for biological, environmental and 
biomedical applications [5, 6, 17-19], Label-free biosensors are grouped into three 
classes: optical, mechanical, and electrical [20-23].
1.1.1 Electrical Label-Free Biosensors
Carbon nanotubes and nanowires are good examples of electrical label-free 
biosensors [10, 11, 24]. An amperometric carbon nanotube (CNT)-based sensor is
4
illustrated in Figure 1-2 [24]. In general, electrochemical amperometric sensors have 
three electrodes [25]: a working electrode, a reference electrode, and a counter electrode. 
This method is sufficient for detecting proteins or DNA, does not consuming much 
energy, and is cost-effective.
By applying voltage bias between working and counter electrodes, an oxidation- 
reduction reaction took place in a solution that contains biomolecules. As a result, 
electron transfer reactions take place over the surface of a working electrode. Since CNTs 
encourage electron transfer reactions more effectively than traditional metals [26], CNTs 
were incorporated to a Platinum (Pt) working electrode by using thermal chemical vapor 
deposition method.
Maehashi et al. used this type of sensor to detect prostate specific antigen (PSA); 
he immobilized PSA monoclonal antibodies (mAb) over CNTs via crosslinkers, and he 
recorded the electrochemical signal by using differential pulse voltammetry (DPV).
After the PSA marker was immobilized, DPV showed a significant increase in 
electrochemical signal and thus indicated the formation of the antigen-antibody complex.
PSA mAb









(a) (b) Potential (V)
Figure 1-2. Amperometric carbon nanotube (CNT) Based sensor, (a) Device setup, (b) 
The electrochemical signal measured by using DPV. The red dashed line represents the 
signal measured when only PSA-mAb immobilized over CNTs; the blue line is the signal 
after PSA is attached to PSA mAb and forming the antigen-antibody complex [24].
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1.1.2 Mechanical Label-Free Biosensors
Mechanical label-free biosensors provide a sensitive method for detecting the 
accumulated analyte mass over receptor. QCM is a mechanical label-free biosensor that 
can measure the change in mass even in pg or ng level.
The operating principle of QCM is based on measuring the changes in quartz 
piezoelectric resonant frequency. When a small mass of matter binds to the surface of the 
quartz, the resonant piezoelectric frequency decreases according to the following relation:
A/  = -C f  Am, Eq. 1-1
where A/  is change in resonant piezoelectric frequency, Cf is crystal sensitivity factor, 
and Am is a change in mass over quartz piezoelectric sensor [5],
QCM has a wide range application, such as biosensors, gas sensors, 
environmental monitoring, and the interactions of surface molecule.
A surface-stress mechanical biosensor with a cantilever is another type of the 
mechanical label-free biosensors [27]. The weight of a biomolecule attached to the 
surface of the sensor and band biomolecules to functional groups on the surface of the 





—  Probe molecule
1—  Silicon nitride 
microcantilever
0— Target binding
Figure 1-3. Schematic of cantilever surface-stress biosensor [27].
1.1.3 Optical Label-Free Biosensors
Optical biosensors have many features such as high sensitivity and accuracy, 
ability to provide a real-time monitoring, negligible environmental noise, electrical 
passiveness, multiplexing capability, and minimum electromagnetic interference. These 
properties enable a wide sensing range, high resolution, and resistance to high 
temperatures, as well as a chemically reactive environment.
The constant improvements of the quality and functionality of optical components 
such as light probes, optical lenses, and mirrors, and advancements in the area of the 
signal processing, make the optical sensing methods attractive for environmental and 
biomedical applications, especially in molecular studies and early biomarker detections, 
because of the high sensitivity. Optical sensing is also compatible with micro and nano 
thin-film devices that are based on silicon or anodic aluminum oxide [28, 29],
Optical sensors can measure and sense many physical, chemical and biological 
components such as pressure, temperature, strain, liquid level, vibration, acceleration,
7
rotation, PH level, magnetic field, flow rate, liquid level, displacement, radiation level, 
humidity level, velocity, electric field, acoustic field, or force, or distinguish between 
chemical species, proteins, or biomolecules, [30-34].
Change in beam intensity for one or multiple light beams, or interacting and 
interfacing between light beams, which cause changes in signal phase, are two principal 
optical sensing methods. All optical sensors have two principal parts: an emitter for 
emitting and transmitting light beams, and a receiver for collecting and receiving signal.
Fabry-Perot Interferometer (FPI) is an optical device that was invented in 1899 
and worked on the principle of multiple-beam interference (Figure 1-4). As shown in 
Figure 1-4, the incident light It is the input signal, the reflected light signal is /r , while the 
transmitted signal is /t .
Fiber probe is used to emit and collect the reflected light. The same fiber probe 
sends the signal to the spectrometer. As a result of a light interference, fringes can be 
observed in different shapes such as rings, strips, and curves.
The path differences between two sequential beams is 6 = 2nd cos 9 , where 6 is 
the angle of incidence. The ratio between the reflected light intensity and the incident light 
intensity can be expressed as:
/ 4 Rsin2 j
7 =  -----------------   g . Eq. 1-2
( 1 -  R)2 + 4Rsin2^
where R is the surface reflectance, /r is the intensity of the reflected light, and It is the 
intensity o f the incident light [35].
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I t
Figure 1-4. Schematic of FPI operating principle [35].
Porous silicon can be used as an FPI sensing platform to sense biomolecules. The 
sensor detects the change in optical thickness (2nd) of the same biological thin film 
layers.
2nd = m \,  Eq. 1-3
where n is the effective refractive index of the porous silicon with all other attached 
biological layers, d is the physical thickness of the porous silicon with all other attached 
biological layers, m is the spectral order of the optical fringes and A is the light 
wavelength [36, 37] in vacuum. Fringes are produced by the interference of light 
reflected from multi interfaces accrued in the structures [37].
Finesse (F) is an important parameter of FPI that reflects FPI resolution. This 
parameter is defined as a numerical value that describes the sharpness of the wave 
maxima. Mathematically, finesse is the ratio between peaks distance AA, to the full width 
half maximum (FWHM) 8A.
7T VF
F = Eq. 1-4
1 -  R ’
Using nanopore platform in FPI sensor (Figure 1-5) has many advantages, such as 
an increased sensing surface area, extended penetration depth of the excited light, and 
amplified optical transducing signal [38], Nanopore platform in FPI sensor, with specific
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characteristics like nanopore diameter of 50 nm and a gap size of FPI cavity of 50 pm, 
provides 20 times improvement in a free spectral range, which is the frequency or 
wavelength spacing between two sequential transmitted or reflected optical intensity 
maxima, and two times improvement in finesse [38].
Broadband light source
pFP cavity
Figure 1-5. FPI device cross-section with a microfluidic channel [39].
1.2 Prostate Cancer Biomarkers
1-2.1 Prostate-Specific Antigen (PSA1
Prostate cancer (PC) is the second most common cause of cancer deaths in the US 
men [40]. According to the American Cancer Society, 233,000 new prostate cancer cases 
appeared in the year 2015, and the mortality rate will be around 13% (30,000 people) 
[41].
There are three options to reduce the number of prostate cancer fatalities and the 
demands on the healthcare system of such disease: 1) decrease the incidence of illness, 2) 
better treatment, and 3) early detection [40].
Modem surgical processes and radiation methods have been improved lately, but 
since PC is a hormonal metastatic disease, the improvement of therapeutic techniques did 
not reduce the mortality of PC.
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The third method to minimize the number of deaths is to improve early prostate 
cancer detection. In order to detect PC early, the most common used method is the serum 
screening of prostate-specific antigen (PSA), followed by the transrectal ultrasound 
guided biopsy. Since these existing methods are not efficient to detect the PC early 
enough, new methods for early detection are needed.
The PSA is a blood serum tumor marker and is the most widely used marker for 
the PC. The PSA was introduced for the first time in the 80’s of the second millennium at 
Roswell Park Cancer Institute in Buffalo, NY by Wang and associates. The PSA is 
classified as one of the most important tumor markers, since it has a substantial role in 
managing men’s lifestyle [40].
The normal level of PSA is less than 2n g/ml. The threshold value for cancer 
detection is < 4.0 ng/ml of PSA in serum, and the gray zone is between 4.1-10 ng/ml 
(meaning that the patient may have a prostate inflammation or a benign prostatic 
hyperplasia (BPH), which increase serum PSA levels of up to 10 ng/ml [42,43], or 
prostate cancer). The PSA is not an ideal marker for PC since it is secreted by normal as 
well as malignant prostates, and PSA levels reflect the size of the prostate rather than 
cancer. An elevated level of PSA might be due to PC or benign diseases, such as BPH 
[40, 44, 45]. Also, the PSA screening test gives too many false positive or negative 
results. The false-positive results lead to an additional test called transrectal ultrasound 
(TRUS)-guided biopsy procedure, and this procedure is invasive, repetitive, and costly.
A man of age 40-50 years has a 34% chance of early occult PC [46], but after 
repeated screening, only one eighth of men will be diagnosed with cancer during his life
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period. The chance of detecting PC clinically for a man who is younger than 50 years old 
is less than 0.3% [44,47].
Although PSA screening is the standard method to detect PC, debate continues as 
to whether to perform the test, at what age a man should have it performed, the 
recommended threshold for the PSA levels, and at what age to stop the screening [45].
In order to improve and enhance the PSA test in the diagnostic of PC, some 
hidden features of the PSA, called PSA derivatives tests, are added to the traditional PSA 
screening. The common PSA derivatives are: PSA velocity, PSA density, age-specific 
PSA, and the ratio of total to free PSA [40].
PSA circulates in the blood in two different forms, freeform and complex form. 
When PSA is attached to proteins, it is called complex PSA, if PSA is not attached to any 
other proteins, it is called free PSA. Total PSA is the amount of free PSA and complex 
PSA combined.
PSA velocity is a method that measures the changing of PSA levels over time.
The PSA levels rise slowly in healthy men and rapidly in PC patients. This method can 
be applied to both PSA and free PSA serum levels. When PSA levels increased at a rate 
more than 0.75 ng/ml per year, it indicates that this person is at higher risk of having 
prostate cancer. Other researchers suggested that the increasing rate threshold of PSA 
levels must be around 25% increment in PSA concentration compared to their previous 
test. For free PSA, any change over 36% in their previous test ratio must be considered 
dangerous [40, 48].
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PSA doubling time (PSADT) is defined as the time needed for levels of PSA in 
the blood to have the double amount. A PSADT less than ten months could indicate 
metastatic disease [49-52].
PSA density is the second concept that can help in enhancing PSA prostate cancer 
screening. PSA density is calculated by dividing the PSA level by the volume of the 
prostate. For example, if  a person has 80 cm3 prostate volume with 8 ng/ml PSA level, 
the calculated density will be 0.1 ng/(ml cm3), and if another person has 40 cm3 prostate 
volume with 8 ng/ml PSA level, the calculated density will be 0.2 ng/(ml-cm3). As a 
result, the individual who has larger PSA density will have more chance to have PC, and 
the person with larger the prostate volume (lower PSA density) will show benign 
histology (see Figure 1-6).
Age-specific PSA is also known as an age-adjusted PSA. It is a concept that 
determines the threshold level of PSA that will indicate that the man of a certain age has 
prostate cancer.
This cutoff level will change over years. According to an age-specific PSA 
concept, a man who is younger than 50 years old should have PSA screening level less 
than 2.5ng/ml, but after 30 years, average levels could be between 0 to 6.5 ng/ml.
PSA: 8.0 ng/ml PSA: 8.0 ng/ml
M m e :8 0 «  Volume: 40 a
PSA Density: 0.1 PSA Density: 0.2
Figure 1-6. PSA density. The right prostate has a volume of 40 cm3 with PSA level 
8ng/ml, and the one on the left has a volume of 80 cm3 and PSA level of 8ng/ml. The 
prostate with higher density might have cancer, while the prostate on the left showed 
benign histology [40].
13
PSA circulates in the blood in two different forms, freeform and complex form 
with protein, such as alpha-1 antichymotrypsin and alpha-2 macroglobulin, most of the 
blood PSA is bound to alpha-1 antichymotrypsin [40, 53]. When PSA is attached to 
alpha-1 antichymotrypsin, it can be detected by immunoassays (a method used for 
detecting proteins, for example enzyme-linked immunosorbent assay (ELISA)) because 
two epitopes are remaining free, when PSA is attached to alpha-2 macroglobulin, all 
epitopes will be attached, and available assays cannot detect this form of complex PSA. 
Free PSA levels are higher in men who do not have prostate cancer [40, 54, 55].
The PSA test is significantly enhanced when the PSA and the free PSA (f-PSA) 
levels are combined together, and the ratio of the free to the total PSA, or the free to the 
complex PSA, is calculated [40]. This test is helpful for men that have PSA levels in the 
gray zone (4.0 to 10 ng/ml) and a negative result from ultrasound biopsy. Catalona et al. 
tested the ratio of free to a total of 773 men who had PSA levels in the gray zone and 
negative ultrasound biopsy, 49% of which had prostate cancer [40, 56].
An important analytical problem appears in calculating the free PSA to total PSA 
ratio because of the difference between PSA manufactured arrays. Some manufactured 
PSA arrays show lower PSA levels than the other, but this issue did not hinder the fact 
that the f-PSA level, combined with the PSA levels, improves the PSA traditional test by 
calculating the probability that a patient has cancer (see Tables 1-1, 1-2) [40, 57]. 
Although PSA screening is the common test for prostate cancer, it is a controversial 
tumor marker. PSA levels are not controlled only by cancer, but it can also change in a 
non-malignant disease like BHP. The patient’s age and race also influence the PSA 
levels in a patient’s blood [44],
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Table 1-1. The relation between PSA blood serum levels and the probability of having 
PC [40].





Table 1-2. The relation between free to total PSA ratio for men who have PSA blood 
serum levels in the gray zone (4-10 ng/ml) and the probability o f having PC [40].






Moreover, highly aggressive cases of PC, which often have neuroendocrine 
features and do not display a significant increase in serum PSA levels, cannot be detected 
by the PSA test. As many as ~15% of PC patients exhibit PSA levels below the adopted 
threshold 4 ng/ml [45].
Because of the poor reliability of the PSA blood test, some new reliable prostate 
cancer markers are needed. The markers should clearly discriminate PC from other 
prostate diseases, predict tumor formation at a very early, preferably premalignant, stage, 
and distinguish aggressive tumors from indolent ones at an early stage [58].
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As a result, the disadvantages of the PSA test are:
1. The PSA test does not give a good idea about progression cancer levels.
2. The PSA test does not reflect the aggressiveness of prostate cancer.
3. The PSA test does not predict the clinical nature of cancer. [59].
1.2.2 Neuroendocrine Marker (NEM)
Neuroendocrine Marker (NEM) is a novel transcript and was recently identified 
from the prostate cancer complimentary DNA (c-DNA) library in our collaborator’s (Dr. 
Shah) laboratory at the University of Louisiana at Monroe (ULM) [60]. NEM produced 
by sub-cloning the complementary DNA in a vector. Then, the genetic structure 
containing NEM c-DNA was applied to a prostate cancer cell line, and after incubation 
and culturing, affinity chromatography obtained the expressed protein [59, 60].
In situ hybridization and immunohistochemistry studies suggest that NEM is 
selectively localized in malignant, but not benign, prostate epithelium [60]. The 
expression of NEM is increased with cancer progression. NEM immunoreactivity (NEM- 
ir) detected in sera of elderly men; serum NEM-ir level in PC patients was three-fold 
greater than those in non-cancer individuals [60-62], suggesting that NEM, either alone 
or in tandem with PSA or other markers, can serve as a valuable tool to reliably diagnose 
populations at risk, and monitor the patients undergoing anticancer therapy. 
Immunohistochemistry of primary prostate tumors has revealed that 47-100% of PCs 
demonstrate foci of neuroendocrine differentiation [59].
Secretory products of neuroendocrine (NE) cells may support growth or increase 
the survival of neighboring tumor cell populations because the cells adjacent to NE cells 
have been shown to display increased expression of mitogenic markers, such as 
proliferating cell nuclear antigen [59] (Figure 1-7).
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NEM Ex
NEM Expression NEM Expression
Figure 1 -7. NEM Immunohistochemistry (IHC) in biopsy samples. (A) Prostate Cancer is 
an epithelial cancer, and NEM Expression is also epithelial. (B) NEM expression is not 
detected in the benign epithelium. (C) NEM expression is detected in early stages of the 
disease. (D) NEM expression increases with tumor progression [59].
To detect NEM, antibodies were prepared in rabbits by injecting them with 
antigens. After immune response took place, blood samples were removed from the 
rabbits and the immunoglobulin fraction of blood sample serum were filtered and used as 
antiserum [59, 60].
Polyclonal and monoclonal antibodies help in NEM detection in both blood and 
tissue, and they give useful information about the cancer grade, whether the cancer is 
metastatic or not, especially for patients with low PSA serum levels [60],
Current evidence also suggests that the tumors of PC patients with “low or 
normal” serum PSA levels usually display high NEM secretions and aggressive growth,
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raising a possibility that the genes associated with neuroendocrine features of the prostate 
may be useful in detecting PC and may also stratify aggressive tumors from the indolent 
ones. In addition, NEM is working as a cancer growth factor too; when NEM binds to its 
receptors located in prostate tissue, cancer will grow and overrun. Blocking the linkage 
between the NEM and its receptors by using an antibody directed against the NEM or its 
receptor would reduce the growth of cancer cells and give some therapeutic benefits [59, 










< X 3 NEM80UN0BVAKT1B00V
Figure 1-8. The prostate cancer therapy by using NEM. (A) Prostate cancer cell 
surrounded by NEM. (B) NEM bounded to its receptors. (C) Cancer cells, growth and 
proliferation. (D) Prostate cancer cell surrounded by NEM. (E) NEM is blocked by an 
antibody directed against. (F) Cancer cell did not grow or proliferate [59].
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The NEM is detected by several methods such as radioimmunoassay, enzyme- 
linked immunosorbent assay (ELISA), fluoroimmunoassay, immunohistochemistry, 
sandwich ELISA, and any other peptide detection techniques [59, 60].
NEM has been found in relatively high levels in blood serum samples from prostate 
cancer patients. NEM novel biomarker can detect cancer in early stages as well as high- 
grade tumors, NEM also may help at the beginning of PC detection, and it could reduce 
additional biopsy procedure (up to 75%). A study sample that consists of 69 samples from 
PC and non-cancer patients exposed that NEM levels of PC serum samples are three times 
higher than in non-cancer patients [65].
NEM also proposed as more reliable PC marker than PSA incorrectly detecting PC 
with less false positive and negative diagnostic. The larger sample size consists of more 
than 500 patients investigated, and the results showed that prostate cancer patients have 
higher NEM levels in blood serum than men who do not have PC [66].
There is a correlation with high PSA levels and NEM levels in the prostate cancer 
patients’ serum. Some prostate cancer patients have low PSA serum levels and higher 
NEM levels. Therefore, NEM could be useful in cancer detection in parallel with a PSA 
test and could help in detecting PSA false positive or negative results.
1.2.3 Other Prostate Cancer Biomarkers
Several novel biomarkers to detect and screen prostate cancer have been 
discovered and tested lately. Those biomarkers are classified according to the source of 
the biomarker: serum biomarkers, tissue biomarkers, and urine biomarkers [49].
1.2.3.1 Blood Serum Biomarkers
Human prostatic acid phosphatase (PAP) is one of the oldest serum biomarkers 
for PC. PAP was discovered in the 1930’s; researchers showed that high levels of PAP
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could indicate the metastatic PC [49]. Other studies concluded that PAP levels are related 
to lymph node disease and metastases. Once the PSA was discovered, the PAP screening 
was stopped.
Early prostate cancer antigen (EPCA) is a series of proteins in blood serum that 
promotes PC in its early stages. These proteins reflect the relation between PC and the 
changes that occur in the nuclear matrix of the prostate. The levels of EPCA proteins are 
higher in adjacent areas of a prostate tumor and exist only in PC patients [49].
In 2005, EPCA had proven to have a high detection sensitivity and selectivity, as 
shown in a Kagawa University study, in which 50 men with PC and ten controls with 
bladder cancer but not prostate cancer. The EPCA method detected malignancy in 94% of 
PC patients and was negative in all controls [49, 67]. Two years later [49, 68], another set 
of proteins that is related to nuclear changes due to the PC were discovered and called 
EPCA-2. The newly discovered proteins were able to detect aggressive PC, as well as 
differentiate men with the organ-confined disease.
Prostate-specific membrane antigen (PSMA) is a 750 amino acid Type 2 trance 
membrane that has three dimensions: intracellular, transmembrane, and extensive 
extracellular sequence [69].
The PSMA is present in very aggressive cancers, and it can better detect high- 
grade tumors than PSA. After several studies on PSMA, assays for that protein were 
developed, such as immunoassays and Western block assays [40].
Pro-PSA is another prostate cancer biomarker. It is similar to PSA in 80% of 
DNA sequences and can have several forms [40]. One form is the enzymatically inactive 
(i-PSA) and another form is the B-PSA found in patients with the BPH. The Pro-PSA
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may reduce the unnecessary biopsy procedures for men with PSA levels in the gray zone 
[40,49],
Prostate cancer biomarkers are not limited to blood serum; Some PC markers are 
discovered from prostate tissue, like Glutathiones-transferase n (GSTP1), which is 
unmethylated in normal human tissue and hypermethylated in prostate cancer samples 
[40, 70].
1.3 Previous Work
Label-free optical sensors based on anodic aluminum oxide (AAO) technology 
apply to several fields, such as environmental studies (gas sensors) and biosensing 
applications. In general, this method is easy to maintain, has a low cost and is simple to 
operate. The operating principle is based on detection of changes in light interference 
within the sensor’s Fabry-Perot cavity. The sensor’s surface changes (analyte binds to 
AAO surface) due to chemical reactions which take place and change the effective index 
of refraction and the surface reflection coefficient (Figure 1-9) [71, 72].
Reflective interference spectroscopy is a label-free optical sensing method based 
on interference of white light over a thin film, and it depends on the product of the 
effective refractive index and accumulated layer thickness. When an analyte binds to the 
sensor surface, a change in the refractive index of the surface layer is detected by 
measuring the shift in the interference pattern [72]. Reflective interference spectroscopy 
usually uses a microfluidic cell to confine the liquid.
NanoporousAAO
Figure 1-9. Schematic of reflective interference spectroscopy. White light from tungsten 
lamp transmitted and received by fiber optic probe, the reflected signal processed by 
spectrometer appeared on display as fringes, when fast Fourier transform applied to the 
reflected signal, effective optical thickness vs. time graph generated [72].
Many studies showed and approved high AAO sensitivity, according to G. Wang 
et al. [73], An AAO sensor is precise and able to detect small concentrations of 
biomolecules, and this advantage will help in detecting certain diseases that have very low 
biomarker levels [73]. They detected biotin diluted in the buffer at different concentrations 
by using electrochemical impedance spectroscopy. This device has two electrodes 
submerged in a buffer solution. The working electrode was made of AAO (see Figure 1-
10), and Ag/AgCl was a reference electrode. When small amplitude of AC signal is applied 
to the electrodes that are submerged in a buffer solution, the impedance is measured as the 
actual system’s response. After biotin is added to the buffer solution and the same AC 
signal is used, it is found that system impedance increased with increasing biotin 
concentration, and the lowest level measured by the sensor is 4 ng/ml [73]. The same group 
also used that device to detect dust mite antigen Der-P2. Der-P2 activates respiratory 
epithelial cells innate in Toll-like receptors (TLRs), which cause acute respiratory disease. 
The dust mite monoclonal antibodies (IgG) were immobilized over the AAO sensor by
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Figure 1-10. Schematic of working electrode that is made of AAO, The electrode are 
used in the detection of the dust mite antigen Der-P2 [74],
The 16-nucleotide DNA oligomers were detected by using the optical nanopore 
sensor [28]. This method showed a high efficiency in detecting both single and multiple 
layers of molecules immobilized over the sensor. When a white light is reflected from the 
sensor surface, interferometric reflectance spectra is detected as Fabry-Perot fringes (see 
Figure 1-11). When biomolecules attached to the sensor surface, Fabry-Perot fringes shift 
due to a change in the effective optical thickness of the porous silicon surface [28].
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Figure 1-11. The Fabry-Perot fringes before (red line) and after (blue line) applying DNA 
over nanoporous sensor [28].
The optical nanopore sensor is efficient in real-time monitoring, especially for gas 
detection. Volatile sulfur compounds (VSCs) causes halitosis, or, in other words, oral 
malodor. VSCs generated when oral cavity proteins disintegrated by bacterial activity. 
Detecting gasses by using a nanoporous optical sensor is less complicated than a traditional 
method of UV-visible and fluorescence spectrophotometry, and it is not as expensive as 
listed methods [75],
1.4 Objectives
The primary goal of this research is to develop a fast, low cost, simple to operate, 
sensitive, specific, and selective PC detection device by using a nanopore thin-film sensor 
biased on nanoporous Anodic Aluminum Oxide (AAO) label-free biosensor, and to test the 
novel biomarker known as neuroendocrine marker (NEM) in parallel with prostate-specific 
antigen (PSA) in PC serum samples.
To reach our goal, we will test nanoporous thin film sensor sensitivity, specificity, 
and accuracy, and then compare human blood serum PSA and NEM levels results from
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nanopore thin-film biosensor with ELISA test results. Finally, we will use the nanosensor 
to determine the levels of NEM and PSA of pathologically confirmed PC human blood 
serum samples.
CHAPTER 2
MATERIALS, INSTRUMENTS, AND METHODS
2.1 Materials
To detect prostate cancer biomarkers by using nanopore thin film, we need 
concrete materials that match experimental protocol [71], which includes 11- 
Mercaptoundecanoic acid (HSC10COOH,99%), N-(3-Dimethylaminopropyl)-N'-ethyl 
carbodiimide hydrochloride (EDC), N-Hydroxysuccinimide (NHS), bovine serum 
albumin (BSA), and glycine. All the materials were purchased from Sigma-Aldrich 
(Milwaukee, WI) and used without further purification. Mouse anti-human prostate- 
specific antigen (PSA) monoclonal antibody (detector mAb) (cat. # ABIN969369, 
clone#5Al 1E9) was purchased from Antibod-Online Inc., Atlanta, GA. The synthetic 
PSA peptide containing the middle region of PSA,was purchased from AVIVA Systems 
Biology, San Diego, CA.
2.1.1 11-Mercaptoundecanoic Acid
Eleven-Mercaptoundecanoic acid (MUA) (Figure 2-1) is an alkanethiol 
commonly used as a foundation for layer-by-layer coatings on gold surfaces. The 
protocol is straightforward and inexpensive. Adsorption to a gold surface requires 
approximately 18 hours [76]. Several parameters control MUA adsorption, such as 
incubation time, the type of the solvent, and MUA concentration. Due to a low toxicity 
and solubility, ethanol is the universal solvent for alkanethiols. Several studies show that
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we can use other solvents instead of ethanol to reduce incubation time, such as hexane. 
However, the results also show that the layer formed is not as organized as the layer 
formed when using ethanol as the solvent [77].
MUA
Figure 2-1. Structure of 11-mercaptoundecanoic acid (MUA) [78].
2.1.2 Phosphate Buffered Saline (PBS)
Phosphate buffered saline (PBS) is the most common buffer solution used in 
biologically related research. This balanced salt solution keeps solution osmolarity and 
pH constant. The primary function of PBS is to maintain biological molecules in perfect 
condition while they are outside their normal growing environment by maintaining pH 
between 7 to 7.6, which is a typical biological range.
To prepare one liter of PBS, start with 800 ml of distilled water, then add 8 g of 
NaCl, 0.2 g of KC1, 1.44 g of Na2HP04, and 0.24 g of KH2P 04. To adjust the pH to 7.4, 
use aliquots of HC1 as needed. Finally, add distilled water to make up a total volume of 1 
liter.
PBS is non-toxic and has identical osmolarity to human fluidics. It is commonly 
used as a wash solution for protein and cell culture experiments [79].
2.1.3 Bovine Serum Albumin (BSA) and Glycine
Bovine serum albumin (BSA) is a protein prepared from serum albumin obtained 
from cow’s blood. It is a large protein comprising 607 amino acids and has a molecular 
weight of 66.5 kDa. Many biological research protocols use BSA due its stability and
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weak affinity during biochemical reactions. It is also used to mimic human fluids. BSA
plays an essential role in blocking nonspecific immunoglobulins during
immunohistochemical reactions [80, 81].
2-1.4 N-( 3 -DimethylaminopropvD-N '-ethyl Carbodiimide 
Hydrochloride (EDC) and N-vdroxvsuccinimide 
(NHS) Carbodiimide Crosslinkers
Two methods can be used to connect proteins or biomolecules over a gold 
surface: passive absorption and covalent bonding using crosslinkers. Passive absorption 
does not provide a stable connection, and biomolecules continuously disconnect from the 
surface and occasionally lose their properties after surface absorption. On the other hand, 
covalent bonding via crosslinkers provides a strong and stable connection that results in a 
controllable protein coat layer. Carbodiimide compounds connect the amino or carboxyl 
groups on antibodies to the free carboxyl or amino groups on bioanalytical platforms.
EDC is the carbodiimide compound used as a crosslink layer in this study. EDC is 
a water-soluble, zero-length carboxyl-to-amine crosslinker. It reacts at biological pH, but 
is most active at pH 4.5. When a protein comes into contact with EDC, an unstable 
reactive o-acylisourea ester bond is formed. To improve EDC efficiency in physiological 













Figure 2-2. EDC linked to the carboxyl group on an antibody in aqueous solution 
generates an unstable, short-lived o-acylisourea ester bond. This bond breaks down in the 
presence of water. The addition of NHS stabilizes the amine-reactive intermediate by 
converting it to an amine-reactive NHS ester, thus increasing the efficiency of EDC 
coupling reactions [82].
NHS is a water-soluble compound that increases EDC workability by providing a 
more stable bond between the protein and crosslinker, called an amine-reactive NHS 
ester bond [82].
2.1.5 SU8
SU8 is a negative photoresist epoxy-based polymer. SU8 (Figure 2-3) is used in 
applications such as electroplating molds, sensors, actuators, micro-to milli-scale 
structures, microfluidic channels, and microelectromechanical systems (MEMS) and it is 
prepared by soft lithography [83, 84].
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Figure 2-3. Chemical structure of SU8 comprising eight reactive epoxy functional groups 
[85].
The numeric eight in SU8 refers to the eight epoxy groups. Upon exposure to UV 
light, this polymer undergoes a photochemical reaction to produce an acid. The acid 
formed in the photochemical reaction acts as a catalyst in the exposed regions during 
post-baking exposure, thus promoting the crosslinking reaction. During crosslinking, a 
zipping process occurs between the epoxy groups that creates a three-dimensional 
network. A broad range of thicknesses (750 nm to 500 mm) with high aspect ratios can 
be obtained from a spin coater [86].
2.1.6 Polvdimethvlsiloxane (PDMS)
Polydimethylsiloxane (PDMS) is a bio-compatible silicon-based organic polymer 
used for fabricating and prototyping microfluidic chips, food additives (e.g., E900), 
contact lenses, medical devices, shampoos, and as an anti-foaming agent in beverages 
and lubricating oils. The PDMS is non-toxic, non-flammable, and inert,and thus useful 
for many biomedical applications [87, 88]. The PDMS empirical formula is (C2H60Si)n
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and its fragmented formula is CH3[Si(CH3)2 0 ]nSi(CH3)3, where n is the number of 
monomer repetitions (Figure 2-4). PDMS is hydrophobic, with contact angles from 90°-
120° with a melting point over 40 °C. PDMS is synthesized from dimethylchlorosilane 
and water by the following reaction:
n Si(CH3)2Cl2 + n H20  -+• [Si(CH3)20]n + 2n HC1.
Besides biocompatibility, PDMS has many advantages, such as low cost and easy 
fabrication, especially for micro-channel modeling [89, 90]. Microfluidic applications of 
PDMS are challenged by aging; that is, the mechanical properties of PDMS can change 
after a few years; thus, it is difficult to permanently deposit this material over metals or 
electrodes. This issue is minimized by attaching the metal to glass, then bonding PDMS 
over the glass after plasma treatment [91].




Figure 2-4. The chemical formula of PDMS [92].
2.2 Instruments
Figure 2-5 displays the experimental setup for the optical biosensor testing that 










Figure 2-5. Experimental setup for optical testing on nanoporous thin-film biosensors.
2.2.1 White Light Source
A versatile tungsten white light source (Figure 2-6) LS-1 model, purchased from 
Ocean Optics, Inc. was optimized for use in the visible and near-IR (NIR) range (360
nm-2500 nm). This light source offers high color temperature (3100 K bulb), efficient
output, and extended bulb life (around 900 hours). The LS-1 is connected to Teflon® 
diffusion discs from the inside to create a diffuse light source optimized for coupling 
fibers as well as for attenuating the source when spectrometer saturation is an issue.
To enhance the spectral envelope in the blue region relative to the red and NIR 
regions (Figure 2-7), we attach a 12.7 mm blue filter called BG-34. The LS-1 is 
distinguished with an SMA 905 connector for simple coupling to the optical fiber and 
spectrometer.
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Figure 2-6. LS-1 white light source.
m m m m
Figure 2-7. LS-1 white light source signal output with (blue line) and without (red line) 
the BG-34 filter.
2.2.2 Spectrometer
The USB 4000 (Figure 2-8) used in our experiments was purchased from Ocean 
Optics, Inc. (USA). Its 3,648-element CCD array detector has powerful high-speed 
electronics support for high spectral response and optical resolution in a single package. 
The resolution of the spectrometer is 0.21 nm and the smallest integration time is 3 ms. 
This model is perfect for experiments that need enhanced electronics, high resolution, and 
fast integration times.
USB 4000 is connected to an optical fiber probe by an SMA 905 connector and 
coupled to the computer via USB 2.0 or serial port. The spectrometer is controlled by a
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Java-based spectroscopy software platform called Ocean View, which works on a range 
of operating systems, such as Macintosh, Windows, and Linux.
Figure 2-8. Photograph of USB 4000 spectrometer.
2.2.3 Probe Holder
To make sure that the angle of the probe and the distance between the probe and 
the sensor is fixed, optomechanical components like a probe holder (Panavise Inc, USA, 
model number PV-301) (Figure 2-9) are needed.
Figure 2-9. Probe holder.
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2.2.4 Optical Probe
The optical probe is connected to the light source and to the spectrometer via an 
SMA 905 connector. The model used in our experiments is QR400-7-VIS-NIR (Figure 2-
10) and the optical probe was purchased from Ocean Optics, Inc. (USA).
This probe is useful for applications that need fast measurements for small sample 
size. The bottom side of the probe is in charge of illuminating and detecting light from 
the same spot. The illumination probe stage has active cooling to minimize the 
overheating risk, which makes this probe suitable for bio-applications and especially for 
molecules with low melting points.
The reflection probe collects light at the same angle as it illuminates and can be 
used for both specular and diffuse reflection applications. The QR400-7-VIS-NIR has six 
illumination fibers around a single collector fiber and a 25° field of view angle (Figure 2-
11). Each illumination fiber generates a cone-shaped light that overlaps at the center of 
the sample and is accurately perpendicular to the read fiber.
Figure 2-10. Photograph of the optical probe.
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Figure 2-11. Schematic of illumination stage of the QR400-7-VIS-NIR probe and the 
cross-section of the optical probe.
2.2.5 Oxygen Plasma Cleaner
The oxygen plasma cleaner (Figure 2-12) uses an oxygen plasma to strip organic 
films (grease, oil, and photoresist materials) from substrate surfaces. By applying the 
oxygen plasma for a short period of time (15 min), any unwanted materials or thin layers 
of photoresist are removed from the sensor top surface and edges.
The oxygen plasma cleaner removes unwanted materials by applying low- 
pressure; in addition, heating over the sensor surface causes partial evaporation of 
contaminants. After that, plasma-abundant energy particles break down unwanted 
particles into smaller sizes that can be sucked off the surface.
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Figure 2-12. Photograph of oxygen plasma cleaner.
2.2.6 Sputter Coating Machine
A sputter coating device is used to coat the sensor with gold. The one used in this 
experiment was manufactured by Cressington Scientific Instruments, Inc. (UK). This 
model has two operating modes: automatic and manual. The automatic mode has two 
options: time controller mode and multi-thickness mode.
2.3 Methods
These experiments are based on optical, biological, statistical, and signal 
processing principles. For optical methods, we describe Fabry-Perot interference from a 
thin nanopore film. In the biological part, the relation between antibody and antigen will 
be noted. Statistical methods, such as linear regression, Person’s coefficent, and the 
coefficient of variation (CV), will be explained. Finally, we further elucidate on cross 
correlation signal processing technique.
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2.3.1 Optical Methods
Fabry-Perot interfemometer (FPI) works on the principle of multiple beam 
interference (Figure 2-13) [93]. FPI is used in other sensing application as well 
(ultrasonic, chemical, biomolecules, and gas) [94, 95]. FPI can also be coupled with 
thermal and electrostatic actuators invested in optical communications by multiplexing 
wavelength division [96], surface plasmon resonance [97], and spectral endoscope optical 
imaging [98].
I f
Figure 2-13. Schematic of Fabry-Perot interferometer work principle [35].
Emitted light lt is the input signal, Ir is the reflected light signals, and It is the 
transmitted signal. A fiber probe is used to emit and collect the reflected light, and the 
same probe sends the signal to the spectrometer. As a result of light interference, fringes 
can be observed in different shapes, such as rings, strips, and curves [93]. This method is 
effective in measuring and monitoring changes in optical thickness.
If the wavelength of applied light is larger than the pore size of nanofilm, then 
optical interference of emitted light will be generated [99,100]. Assuming that the film is
optically transparent, and using the Fabry-Perot effect, the optical reflectivity spectrum 
model is as follows [101]:
38
Z /  2nLn\3 /  2nLn\  1 /  2nLn\‘‘ /  4nLn\  _  .
/r = itv cos I )  l sin“ ) + s ( cos— ) r - sin— )■ Eq- 2_1
where Ir is the intensity of reflected light of wavelength X, L is the thickness of the film, 
and n is the refractive index of the film.
When light is applied perpendicularly to the nanopore film surface (Figure 2-14), 
each fringe will have the following relation [36,101-107]:
2neffL = mA, Eq. 2-2
where neff is the effective refractive index of all the layers of nanopore substrate with 
thin biological films on top of it, L is the optical thickness of the film, m is the spectral 
order of the optical fringe, and X is wavelength.
From Eq. 2-2, the term 2neffL is called the effective optical thickness (EOT). 
EOT is a function of optical thickness as well as effective refractive index.
The effective refractive index neff is a unitless number and is a function of the 
materials and the porosity (P) of the nanopore thin film structure [108]. Using 
Bruggeman’s equation, neff can be calculated as follows [109]:
1 ^ , 0 ,  Eq. 2-3
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Figure 2-14. Interference fringes when the light is applied perpendicularly to the silicon 
nanopore film [101].
Localized surface plasmon resonance (LSPR) is a useful method to detect small 
changes that accrue to the sensor surface refractive index [110]. When an analyte is 
applied over a sensor surface, the refractive index and optical thickness will change. As a 
result, in comparison with the original signal (Ir l), the reflected Fabry-Perot fringe 
signal is shifted (Ir2) due to changes in the surface characteristics (Figure 2-15) [28],
We can measure the changes in nanopore thin film surface characteristics using 
three different methods [111]. The first uses the nanopore thin film as a waveguide, with 
the congruous modes as transduction variables [112-114], The second method finds
optical changes by measuring the shift that occurs at the Fabry-Perot fringes peaks [110].
The last method measures the effective optical thickness (EOT) by applying Fourier 






Figure 2-15. Wavelength shift (AX) due to change of surface characteristics of nanopore 
thin film. Irl represents the reflected fringe signal after applying antibody. Ir2 represents 
the reflected fringe signal after biomarker attached to antibody. AX is the difference 
between Irl and Ir2 [65].
2.3.2 Anti gen-Antibody (Ag-Abi Relation
An antibody is a large molecular weight protein that has a Y-shape and relates to 
the family of globular proteins called immunoglobulins (Figure 2-16). Antibodies can 
attach to and mark foreign targets (antigens) like viruses and bacteria for destruction by 
the immune system [118].
Antibodies (Ab) generated by an individual for a specific antigen have the same 
structure, but they are unique in function since they comprise different amino acid 
sequences. Antibodies are the most diverse proteins known [118]. They are composed of 
three fragments, two of which are identical and used as antigen (Ag) binding sites.
These identical fragments consist of one heavy chain and one light chain polymer 
connected to form the paratope, which is the antigen binding site. The two identical 
fragments are called the antigen-binding fragments (Fab). The third fragment (Fc) forms 
the base of the Y-shaped macromolecular structure and is crystallized during low- 








Figure 2-16. Schematic 3D model of an antibody [118].
The antigen-antibody reaction can be described as follows [119,120]:
Ag + Aft —* AgAfo. Eq. 2-4
The association rate [va) of the antigen-antibody reaction is calculated as:
v a = ^[A^tAf,], Eq. 2-5
where k a is the association rate constant, is the concentration of the antigen, and 
[Ab] is the concentration of the antibody.
At equilibrium, the mass action law states:
= kd , Eq. 2-6
where kd is the dissociation constant and [A^A*,] is the concentration of the antigen-
antibody complex. This simplifies to:
Eq. 2-7
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The lower that magnitude of kd, the higher the affinity of antigen-antibody binding.
The total concentration of antibody [Ab]T is the summation of [Afc] and [ A ^ ] :
[ A b l r  = Mi>] + • Eq. 2-8
As a result, the mass action law can be rewritten as:
1 s J l  + k u [Aa]
Eq. 2-9








Figure 2-17. Antigen-antibody saturation binding curve [119].
2.3.3 Statistical Methods
Linear regression is one of the most commonly used statistical methods. Using 
linear regression to find Pearson’s coefficient, we can find the relation between two 
variables and their closeness of fit [121].
In this research, we plot a linear regression curve to find the relation between 
levels of prostate cancer markers (PSA and NEM), detected using a nanopore thin film
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method, and marker levels, detected using the enzyme-linked immunosorbent assay 
(ELISA). Mathematically, we perform a linear regression as:
y  = Bq + Bxx , Eq. 2-10
where B0 is the y  intercept and B1 is the slope. This is rewritten as:
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We also use confidence of determination (/?2) to find how close the data points 
are to a line of best fit:
R2 = — , Eq. 2-15
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where SSR is the sum squared regression and SST is the sum squared total. Pearson’s 
coefficient is the square root of confidence of determination.
To validate nanopore thin film precision, we use the coefficient of variation 
method (CV) [121], which assesses the performance of the assays.
The CV is a dimensionless numeric calculated by dividing the standard deviation 
of duplicate measurements of biomolecules over a sensor at certain concentrations, i.e., 
PSA prostate cancer serum marker at concentration 160 pg/ml divided by the mean of the 
duplicate measurements. If we have a poor coefficient of variation, then the error may be
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caused by poor experimental techniques, such as pipetting [122], thawing and freezing, 
vortexing, or centrifugation.
2.3.4 Signal Processing Techniques
To find the diffemce between two reflected signals from porous AAO sensor
surface we measured the shift that occurred on the Fabry-Perot fringes peaks (Figure 2-
18), and we compared them (Figure 2-19) with the results that generated by using cross­
correlation MATLAB code (Appendix).
The cross-correlation between two signals x and y is given by:
where x is the time shift between signals x and y.
Figure 2-18 shows the difference between the signal generated when white light is 
reflected from the porous AAO nanosensor after PSA antibody immobilized (red signal), 
and the signal that is generated when white light reflected from the porous AAO 
nanosensor after PSA biomarker attached to PSA antibody (blue signal). The difference 
between fringe peaks maxima are AM= 7.62 nm, AM= 7.02nm and AM=7.29 nm. The 
average of AM, AX2, and AM is 7.312 nm. (The standard deviation of AM, AM, and AM 
-  0.3, CV= 0.041). From the cross-correlation method, the difference between both 
signals is 7.4405 nm. The average wavelength shift calculated as the difference between 
maxima and was highly correlated with that calculated from the cross-correlation method 
(Person’s coefficient = 0.901).
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Figure 2-18. The wavelength shift between Fabry-Perot fringes (PSA antibody (red 
signal)) and PSA biomarker (blue signal). The average of wavelength shifts (AA.1, AX2, 
and AA.3) = 7.31 nm.
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Figure 2-19. Comparison between the cross-correlation method and the peak estimating 
method for finding the wavelength shift between two signals (Pearson’s coefficient = 
0.901).
CHAPTER 3
SENSOR DESIGN AND FABRICATION
3.1 Sensor Design
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Figure 3-1. The block diagram for patterned AAO nanoporous sensor fabrication.
Anodic aluminum oxide (AAO) nanopore thin films are used in many applications, 
such as energy conservation and storage devices (due to its high surface area structure), 
nanomaterials, biosensors, and gas sensors [108]. Porous silicon surfaces with AAO thin 
films are used as label-free optical biosensors, although many studies show that porous 
silicon sensors have drawbacks, such as, rapid degradation and poor stability [72]. AAO
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nanopore sensors have a vertically organized and highly ordered pore structure in a nearly 
hexagonal pattern [123]. AAO pore diameter is controllable and has a range of 20 nm-300 
nm. Other surface characteristics, such as pore distance and pore depth, are controllable as 
well, with a range of 25 nm-500 nm and 1 pm-200 pm, respectively [72]. Compared with 
porous silicon, porous AAO sensors have greater thermal and pH stability, and greater 
flexibility in controlling pore structure [72,116].
When porous AAO is used as an optical biosensor, we apply white light over the 
sensor surface. The reflected interference signal depends on the pore characteristics, such 
as diameter, length, surface adjustment, and pore wall thickness [72].
In general, an AAO membrane can have one of two morphologies that have been 
established based on the chemical nature of electrolytes (Figure 3-2) [124, 125], For 
example, electrolytes with a pH range between 5 and 7, like oxalate, generate nonporous 




Figure 3-2. Two different AAO morphologies formed by an acidic electrolyte (porous) 
and a natural electrolyte (nonporous) [108].
48
An anodic oxide layer over aluminum has a uniform thickness and does not degrade 
in the electrolyte solution. During anodic oxide layer formation under constant voltage, the 
current density of anodization [/) decreases with time (t) in an exponential manner.
The term (J) is the summation of ionic current (Ji) and electronic current (Je). When 
high electrical field (£) is applied over the oxide layer, J approximately equals Ji. As a 
result, the relation between and E can be written as [108,128]:
where J0 and (J are temperature-dependent material constants. E is a function of anodization 
voltage (I/) and is inversely proportional to barrier thickness (tb) as in the following 
relation [129]:
The anodic oxide layer thickness does not depend on applied anodization voltage 
(V) and can reach several micrometers [108]. At constant V the current density-time 
curve can be split into four major phases (Figure 3-3). Phase one starts directly after 
applying constant voltage V over an aluminum sample. At the moment V is applied, /  
immediately reaches a maximum value and a thin layer of oxide barrier begins to 
establish on the aluminum surface that has contact with the electrolyte solution.
Then, the thickness of the oxide layer increases quickly. As a result, surface 










Figure 3-3. Current density of anodization versus time curve for the four phases of AAO 
formation under constant voltage [108].
In phase two, straight parallel-aligned initial pores form in the oxide barrier layer 
[130]. The mechanism of primary pore formation can be described by showing that the 
current density of anodization, J, attacks the weak positions at the oxide layer surface 
caused by cumulative tensile stress [126, 131, 132].
During phase two, some initial pores continue to grow while others stop growing. 
Additionally, the total surface resistance decreases in phase two, which leads to 
progressively increasing values of J to the regional maximum [108].
In Phase 3, pores continue growing. Finally, in Phase 4, the current density of 
anodization J decreases from the local maximum to a stable value and a dynamic 
equilibrium of a forming and dissolving anodic oxide layer is established [108, 132].
The AAO membrane has a unique unit cell structure that consists of three major 
parts (Figure 3-4). The first part is the skeleton of the hexagonal inner layer. This part is 
made by the mutual internal walls between the unit cells. The second part, which is 
located between the inner layer and the central pore, is called the outer layer. The last part 
is the internal rod, which is located inside the inner layer [108].
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Porous AAO unit cell structure parameters, such as pore diameter Dp, pore wall 
thickness dw, pore length lp, pore density pp, interpore distance Oint, barrier layer 
thickness tb, and porosity P have relationships as follows:
Dint ~ Dp + 2 dw , Eq. 3-3
/  2 \
Pv = Eq. 3-4
Eq. 3-5
These parameters primarily depend on anodization voltage, V, anodization time, 
electrolyte type, and anodization process temperature [108,133,134].
,* 1 Outer layer Interstitial rod (1*1
CL
Inner layer Barrier layer
Figure 3-4. a) Porous AAO unit cell structure major parts; (b) cross-sectional view of 
porous AAO that shows unit cell structure parameters [108].
Pore diameter Dp, pore wall thickness tw, and pore length lp are the most 
important parameters of porous AAO and have a strong impact on reflectometric 
interference spectroscopy (RIfS) signals [72]. Pore diameter Dp is controlled by changing 
the anodization voltage [135, 136]; for example, anodization voltage of 30 V-70 V 
generates AAO pore diameter of 20 nm-60 nm, with pore distance ranging from 60 nm- 
100 nm. The relationship between Dp and the anodization voltage is linear (Figure 3-5) 
[72].
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Pore length lp can be adjusted by changing anodization time since pore growth is a 
time-dependent process. Nonetheless, the rate of AAO pore growth is not fixed at different 
anodization voltages; however, we can find the rate of pore length growth at constant 
anodization voltage (Figure 3-5) [136].
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Figure 3-5. (A) Pore diameter is controlled by anodization voltage with a linear relation. 
(B) The impact of anodization time over pore length at constant voltage (50 V) [72].
3.1.1 The Effect of AAO Pore Diameter (Dr) on the White 
Light Reflected Signal
To find the relation between pore diameter and white light reflected signal, we 
must eliminate other parameters, such as pore length, by keeping it at a constant value.
The significant impact found was the number of Fabry-Perot fringes obtained from AAO
surfaces (Figure 3-6).
The increments in the number of fringes due to pore diameter increase are 
measured as the increments in the number of reflected light beams from the AAO 
surface.
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There is no typical pore diameter for a porous AAO sensor, and Dp depends on 
the size of molecule to be detected. For small molecule detection, a higher shift in Fabry- 
Perot fringes is expected, with better sensitivity when a small Dp is used.
—  21 nm 10 fringes
—  25 nm 13 fringes
—  40 nm 18 fringes
m TOO
Wavelength /nm
Figure 3-6. Increase in fringes as the AAO pore diameter Dp is increased from 21-40 nm 
[72].
Controlling Dp by changing anodization voltage affects pore wall thickness dw and 
interpore distance Dint. As a result, it is hard to evaluate the effect of those parameters 
separately. Pore wall thickness is decreased by applying 10% wt phosphoric acid over the 
AAO surface in a process called “pore widening,” which is time-controlled.
Reducing the value of dw leads to increasing in Dp (Figure 3-7). Experiments show 
that after applying a widening solution over AAO for more than 65 mintues, the pore walls 








Figure 3-7. SEM images of AAO nanoporous sensor, (a) AAO sensor with Dp= 30 nm. dw 
is decreased after applying 10%wt phosphoric acid over AAO surface for (b) 20 minutes, 
(c) 40 minutes, and (d) 50 minutes, (e) Obtained Fabry-Perot fringes during the pore- 
widening process[72].
3.1.2 The Effect of AAO Pore Length (lr ) on the White 
Light Reflected Signal
Pore length lp of AAO has the same effect on the white light reflected signal as 
AAO pore diameter Dp. The Fabry-Perot interference fringe patterns increase as lp 
increases (Figure 3-8). AAO, with lp less than 2.5 pm, shows few or no Fabry-Perot 
interference fringe patterns. The best lp range to have significant number of fringes with 
high intensity is 2.5 pm-5 pm. When lp is more than 5 pm and less than 10 pm, the 
number of fringes increases; however, this increase affects the intensity of the signal by 
decreasing amplitude intensity, thus making it hard to analyze the generated signal. If lp 
is more than 10 pm, then fringes will be very small (“baby fringes”). For AAO with lp 
more than 12 pm, no fringes are observed using RIfS. The relation between the 
increasing number of fringes and changes to intensity by increasing lp can be clarified by 
the increment in the number of reflected light within AAO pore, which leads to more
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fringes. However, the light intensity is reduced due to lost energy caused by multiple 
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Figure 3-8. Relation between pore length lp and the white light reflected signal over the 
AAO sensor surface. At lp less than 2.5 pm, few fringes are generated. With increased lp, 
the number of fringes is increased with decreasing reflected signal intensity [72].
3.1.3 The Effect of AAO Pore Surface Modifications
The reflectivity of the AAO sensor surface affects both the light reflectance from 
the surface and the interference signal [137]. Coating our sensor surface with ultra-thin 
metal modifies the fringe shape and the reflected signal intensity (Figure 3-9).
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Figure 3-9. Improvement of reflected signal before and after coating AAO sensor with 
gold. (A) Reflected signal from non-gold-coated AAO sensor surface before (black line) 
and after (red line) applying biomolecules. (B) Reflected signal from gold-coated AAO 
sensor surface before (black line) and after (red line) applying biomolecules. Compared 
with B, it is hard to find the difference between the two reflected signals from the gold 
and non-gold-coated AAO sensors [108].
Many metals are used as a coating layer over AAO top surfaces, such as gold, 
silver [78, 138], platinum [72], and copper [139, 140]. Gold (Au) is the most common 
metal used to make a thin layer AAO sensor surface [78] because it is inert and does not 
form any oxide layer below its melting temperature [141], Au provides excellent 
chemical stability to the sensor surface.
One more advantage that makes Au more attractive as a surface coating is the 
ability to make extraordinary contact with alkanethiols, which are the building blocks of 
the self-assembled monolayer [101, 142,143].
The best enhancement of the reflected signal occurs when the thickness of the 
gold surface coating is between 4 nm and 10 nm. A gold layer with a thickness of more 
than 10 nm will not enhance the signal.
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After the AAO is coated with gold, the pore diameter is reduced. Au thickness, 
therefore, is optimized to ensure the gold does not block the sensor pores. This research 
uses an AAO sensor with the following characteristics:
Pore diameter Dp = 55 nm, pore length lp = 5 pm, pore density = 5.5 * 109 pores per cm2, 
pore period = 145 nm, poricity = 34.4%, and Au coat thickness = 5 nm.
3.2 AAO Sensor Fabrication
We use indium tin oxide (ITO) glass (Nanocs, Inc., IT100-111-25) to fabricate a 
patterned AAO sensor (Figure 3-10). ITO glass is used because it is a conductive material 
(sheet resistance value 100 O/square) and helps transport electrical current through the 
surface smoothly [144]. Patterned AAO sensor fabrication goes through three major 
steps: anodization, photolithography, and etching.
ITO GlassAAO patterns
3 inches
Figure 3-10. Fabricated AAO patterns over ITO glass.
3.2.1 AAO Sensor Fabrication
The first step in the anodization process is to wash the ITO glass by sonication for 
five minutes in deionized (DI) water, then five minutes in acetone, followed by five
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minutes in isopropyl alcohol, and finally, sonication for five minutes in DI water again. 
Then we bake the cleaned ITO glass for five minutes.
In the next step, we deposit an aluminum layer with a thickness of 8 pm over the 
ITO glass surface using an E-beam evaporation device. We consider surface smoothness 
after the aluminum layer is deposited, since it is a significant factor in the fabrication 
process [145,146].







Figure 3-11. Schematic of two-step anodization instrument [147].
During anodization, a chemical reactions take place. The chemical reaction during 
alumina (A120 3) formation is:
2A1 + 3H20 ±7 A120 3 + 6H+ + 6e~. Eq. 3-6
Part of A120 3 at the alumina-electrolyte interface is dissolved by the following 
reaction:
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A120 3 + 6H+ -» 2A1+3 + 3H20 . Eq. 3-7
At the barrier layer, aluminum will dissolve:
2A1 -> 2A1+3 + 6e~ . Eq. 3-8
At the cathode, hydrogen gas (H2) will develop:
6H+ + 6 e ~ -» 3H2 . Eq.3-9
The two-step anodization process procedure is as follows. First, we apply the Al- 
coated ITO glass inside the anodization device (Figure 3-11) for 10 minutes with 0.3 M
oxalic acid as the electrolyte and apply DC voltage (45 V) at 2 °C. This process is called
step-one anodization. Second, we etch the sample using 0.2 M chromic acid and 0.4 M 
phosphoric acid at 65 0 . At this stage, no voltage is applied. Finally, the nanopores are 
developed in step two anodization and etched in 0.3 M oxalic acid for 40 minutes under 
the same conditions applied in step one anodization. After the two-step anodization 
process is complete, we rinse the achieved AAO sensor (Figure 3-12) with DI water.
Figure 3-12. SEM of porous AAO sensor surface.
3.2.2 Photolithography
Since the whole surface of the ITO glass will be covered by a porous AAO layer 
by the end of the two-step anodization, photolithography is applied to make a patterned 
AAO device.
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We start the photolithography process by depositing a thin film of aluminum (150 
nm thick) over the porous AAO surface by thermal evaporation. Then, a positive 
photoresist (AZ 1512) is applied to the sensor surface and spin-coated at 4,000 rotations 
per minute (rpm), followed by soft-baking for 50 seconds at 95 °C.
Afterwards, patterns are transferred to the photoresist layer by applying a 416 nm 
light at an exposure dose of 70 mj/cm2 through a photomask, followed by baking for 50 
seconds at 105 °C.
The photoresist layer not covered by the photomask during light exposure is 
removed by submerging the sample in an AZ developer for 25 seconds. By this step, 
patterns are implanted over the AAO sensor surface at the spots protected by the 
photomask.
3.2.3 Etching
The etching process starts when we apply the sample in an aluminum etching 
solution for 35 seconds. This step removes the unprotected A1 layer. The etching solution 
consists of H3P04:CH3C00H: HN03: H20 (80:5:5:10 by weight %).
Then, the unwanted AAO layer is etched out by submerging the sample in a 
mixture of 0.2 M chromic acid and 0.4 M phosphoric acid for 1.5 hours.
Finally, we remove the remaining photoresist using acetone and etch out the 
deposited aluminum layer using an aluminum etching solution. The patterned AAO 
fabrication process is showen in Figure 3-13.
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Figure 3-13. Patterned AAO fabrication process, (a) Clean ITO glass, (b) Deposit 
aluminum thin film, (c) AAO generated after two-step anodization process, (d) Deposit 
another aluminum layer to create patterns and apply photoresist layer and light exposure 
through a photomask, (e) Etch unprotected aluminum layer using an aluminum etching 
solution, (f) Etch unwanted AAO layer, (g) Remove photoresist layer by action and etch 
the second deposited aluminum layer.
After the fabrication process is completed, we coat the sensor with a 50-A gold 
layer. To evaluate if our sensor is fabricated precisely, we apply white light over the 
sensor surface and observe the reflected signal generated (Figure 3-14). A poorly 
fabricated sensor generates low-intensity fringe signals and sometimes no fringe signal, 
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Figure 3-14. Well-fabricated AAO sensor (red line) versus poorly fabricated AAO sensor 
(blue line). Fringes generated by a well-fabricated sensor have better reflected intensity 
than those produced by a poorly fabricated sensor.
CHAPTER 4
PROSTATE CANCER BIOMARKERS DETECTION
4.1 Experiment Protocol
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Figure 4-1. Flow chart of the experimental setup.
4.1.1 Antibody Immobilization and Antibody Detection
The gold-coated AAO surface was first cleaned with O2 plasma for 15 minutes. 
This step was followed by a self-assembled monolayer (SAM) process (Figure 4-2), in 
which the sensor is incubated in a mixture of 1 mM HSCIOCOOH and HSC80H with a 
molar ratio of 1:10 in absolute ethanol solution overnight. The SAM was activated by 
incubation in phosphate buffer solution (PBS; 10 mM, pH 7.0) containing 0.5 mM of 
EDC/NHS for 2 hours. The activated SAM was rinsed with the 10 mM PBS, and then 
incubated with a freshly prepared 10 mM PBS solution containing 10 pg/ml of the
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detector mAb for 18 hours at 4 °C. The device was then rinsed with the PBS, followed by 
0.2 M glycine-PBS solution for 10 minutes to deactivate the remaining active sites at the 
SAM. This step avoided non-specific binding between the SAM and the antigens. It was 
followed by measuring the reflected single from the sensor surface after the antibody 
immobilized. Then, different concentrations of biomarker solution was applied to the 
antibody-coated AAO sensors and incubated for 60 minutes at room temperature. Then, 
the sample was rinsed with PBS to wash away unbounded biomarker molecules. This 
step was followed by measuring the reflected single from the sensor surface after 
biomarkers applied. Finally, we measured the shift of the optical fringes for each sensor.
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Figure 4-2. Illustration of the protocol for the self-assembled monolayer (SAM) 
formation on the Au-coated AAO surface, antibody (Ab) immobilization and NEM 
detection.
4.1.2 Nanosensor Surface Functionalization and Characterization
The nanosensor was subjected to a step-by-step surface functionalization 
procedure of the Au-coated AAO surface. This well-established method allows the
63
formation of a mixed SAM of alkanethiols by the adhesion reaction of the thiol group on 
the Au-coated surface [148]. After EDC/NHS is added on the surface, the carboxylic 
groups of amine-reactive intermediate is formed. Due to their positive charge at 
physiologic conditions, primary amines are usually the outward-facing components of the 
proteins. Hence, they are generally accessible for conjugation without denaturing the 
protein structure. As a result, the detector mAbs for NEM or PSA can be covalently 
attached to the top of the mixed SAMs. In order to eliminate or mitigate the non-specific 
biological binding, the remaining active amine-reactive intermediate groups are 
deactivated by the amino acid glycine. Thereafter, the mAbs are conjugated to the 
nanosensor surface and ready for detecting NEM or PSA.
4.2 Nanosensor Validation
For the validation of the nanosensors, key assay parameters such as specificity, 
sensitivity, accuracy, and precision were critically evaluated as per the requirements of 
international guidelines [149,150]. First, we tested whether the presence of a high 
concentration of unrelated protein(s) influences the binding between the detector 
antibody and the sensor. We compared the binding of NEM mAb or PSA mAb with the 
sensor in the presence/absence of BSA (0.15 mg/ml). Second, multiple sensors were used 
to determine the standard curve for NEM or PSA, and the results of different batches of 
sensors were compared to ascertain the reproducibility of the sensors. Third, aliquots of 
human serum samples were tested in multiple dilutions to determine the upper and the 
lower serum volume detection limits. All samples were tested in duplicate and only the 
results with a coefficient of variation (CV) <20% were accepted.
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Sensor efficiency: To determine the accuracy of nanosensor measurements, 
known amounts of NEM or PSA antigens were added into pooled serum aliquots. The 
amount of the antigen(s) determined by nanosensors was compared with the expected 
amounts of antigen.
Comparison of nanosensors with ELISA: The serum samples left over from an 
earlier study [115] that used ELISA to detect the antigens were used in nanosensor 
assays. The results from both studies were compared by using Pearson’s correlation 
method.
Comparison of the detection ability of NEM and PSA by using nanosensor tests 
applied to pathologically confirmed prostate cancer blood serum samples (cancer blood 
serum samples and negative control blood samples were provided from ULM College of 
Pharmacy).
We used one site-specific binding (Y) equation to generate standered curves 
(Figure 4-3) for antibodies and biomarkers. To use this equation, we must have already 
subtracted off any nonspecific binding. At high biomarker concetration, all of the binding 
sites become occupied. As a result, the standard curve reached the saturation point.
Bmax%
E<" 4-1
where X is the concentration of the ligand, Bmax is the maximum binding in the same 
units as Y, and kd is the dissociation constant.
After we generated the standered curves, we converted the x-axis into a 
logarithmic (Log10) scale to find the linear region of the curve.
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Figure 4-3. One site-specific binding saturation curve.
4.2.1 Antibody Optimization
Before we start detecting biomarkers, we selected the antibody concentration that 
we are going to immobilize over porous AAO sensor surface. This step is important 
because all experiments should be applied under the same conditions.
To optimize NEM antibody (Figure 4-4), we immobilized different NEM 
antibody concentrations over different porous AAO sensors, and we measured the 
reflected signal from porous AAO sensor; then we applied fixed concentration of NEM 
biomarker (8 pg/50 pi) over the sensors. After 60 minutes of incubation, we measured the 
reflected signal again and calculated the wavelength shift between antibody signal and 
biomarker signal.
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Figure 4-4. NEM antibody optimization.
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To optimize the PSA antibody (Figure. 4-5), we used the same method of NEM 
antibody optimization.
><
Figure 4-5. PSA antibody optimization.
When the concentration of antibody is increased, the shift between antibody 
signal and biomarker signal is increased. The selected concentration of PSA and NEM 
antibodies is 10 pg/ml.
4-2.2 Porous AAO Nanosensor Detecting Limits
After we selected the concentrations of PSA and NEM antibodies, we will 
measure the lowest and the highest concentration of NEM (Figure 4-6) and PSA (Figure 
4-7) biomarkers that porous AAO sensor can detect. NEM biomarker concentrations 
tested were 0, 0.025, 0.05, 0.1,0.2, 0.4, 0.8,1.6, 3.2, 6.4,12.8,25.6, 51.2 and 102.4 pg/50 
pi. The lowest concentration of NEM detected by AAO porous nanosensor was 0.1 pg/50 
pi (2 pg/ml), and the curve reaches the saturation point at 25.6 pg/50 pi (0.512 ng/ml).
For PSA, the lowest concentration detected by AAO porous nanosensor was 1 pg/50 pi 
(20 pg/ml), and the curve reaches the saturation point at 50 pg/50 pi (1 ng/ml).
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Figure 4-6. NEM biomarker detection limits by using porous AAO nanosensor. The 
lowest concentration and the highest concentration detected were 0.1 pg/50 pi and 25.6 
pg/50 pi, respectively.
Figure 4-7. PSA biomarker detection limits by using porous AAO nanosensor.
4.2.3 Biomarkers Standard Curves
To generate a standard curve for NEM and PSA biomarkers, different 
concentrations of NEM and PSA were prepared from stock solution. NEM and PSA 
concentrations in stock solution are 5 mg/ml and 1 mg/ml, respectively.
The concentrations that we prepared to generate standard curves were 32,16, 8,4, 
2, 1 and 0 pg/50 pi for PSA (see Figure 4-8), and 16, 8, 4, 2, 1, 0.5 and 0 pg/50 pi for 
NEM (see Figure 4-9). All diluted solutions were prepared by using serial dilution
•  .2
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method. PSA and NEM standard curves show the relationship between biomarker 
concentration and wavelength shift between the signal that generated from antibody 
coated sensor surface and the signal that generated after antigen-antibody complex 
formed. The relation between biomarker concentration and wavelength shift is nonlinear; 
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Figure 4-9. NEM standard curve.
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4.2.4 Reproducibility
To test the reproducibility of the nanosensors, the assays with normal standard 
curves were performed on three randomly selected sets of chips and run under the same 
conditions on three different days. Figure 4-10 demonstrates the reproducibility of the 
response. The standard deviation over the mean of each point were 0.08 at 1 pg, 0.12 at 2 
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Figure 4-10. NEM standard curves using three separate sets of sensors on different days. 
Sensors 1, 2, and 3 were the fabricated AAO nonporous thin film (Figure 3-9).
4.2.5 Specificity
To test the specificity of this detection method, we compared the shift of the 
fringes when NEM solution was applied to the sensor versus concentrated bovine serum 
albumin (BSA) solution (15 mg/ml). After 1 hour incubation, the sensor was rinsed with 
PBS buffer. The measurements in Figure 4-1 IB demonstrate no clear shift of the 
transducing signals before and after the BSA applied. In contrast, NEM solution gave a 
clearly observable shift (Figure 4-11 A), demonstrating that the sensor can specifically 
detect the antigen even in the presence of large protein concentrations as long as the
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antibody is specific. Also, we applied NEM biomarker over PSA mAb and PSA over 
NEM mAb to check if any unspecific binding occur (Table 4-1).
The results indicated no shift of the fringes when NEM biomarker was applied 
over PSA mAb, or when we applied PSA biomarker over NEM mAb.




PSA antibody (5 pg/ml) + NEM biomarker (8 pg/50 p i ) 0.14
PSA antibody (2.5 pg/ml) + NEM biomarker (8 pg/50 pi) 0.067
NEM antibody (10 pg/ml) +PSA biomarker (2 pg/50 pi) 0
NEM antibody (10 pg/ml) +PSA biomarker (4 pg/50 pi) 0.047
NEM antibody (10 pg/ml) + BSA (1.5 mg/ml) 0.107
NEM antibody (10 pg/ml) + BSA (0.15 mg/ml) 0.075
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Figure 4-11. (A) Typical transducing signals (average shift of interference fringes 4.81 
nm) from the optical sensor after the NEM (16 pg/50 pi) is applied, incubated, and then 
rinsed using the buffer solution PBS in the sensor. (B) Specificity and selectivity test: 
transducing signal from the sensor after BSA solution is flowed, incubated, and then 
rinsed using buffer solution PBS in the sensor is negligible (average shift 0.017nm).
4.2.6 Accuracy
To test the accuracy of nanosensor, we prepared pools of sera obtained from 
normal subjects and added known amounts of antigen (either NEM or PSA). We then 
measured the concentrations of NEM or PSA in all pooled sera in the same assay (Table 
4-2). The detected value of added antigen was determined. The accuracy (the ratio of 
measured amount to calculated amount) of the detection of the known amounts of added 
antigen varied from 93% at the lowest added concentrations (1 pg added PSA) to 76.7% 
at the highest added concentration (4 pg added PSA).
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Table 4-2. Accuracy test.









0.5pl serum + 
49.5pl PBS
0.504 0.978 0.978
0.5pl serum + 
lpg PSA + 
48.5pl PBS
0.898 1.978 1.84 93
0.5pl serum + 
2pgPSA + 
47.5pl PBS
1.215 2.978 2.64 88.6
0.5pl serum + 
4pg PSA + 
45.5pl PBS
1.565 4.978 3.82 76.7
4.2.7 Comparison of NEM Nanosensor Assay with NEM ELISA
We then compared our earlier NEM ELISA standard curve (Figure 4-12a) with 
the NEM nanopore thin-film sensor standard curve (Figure 4-12b). To generate NEM 
ELISA standard curve ELISA microtiter plates were coated with 23 ng NEM antibody 
per well overnight at 4 °C, followed by washing of the plates and the addition of BSA 
solution (2%) as blocking solution. Then the samples were added and incubated for one 
day. The next day, the biotinylated NEM was added to the wells and incubated for 3 
hours at 37 °C. After that, we added and incubated streptavidin-horseradish peroxidase 
conjugate [164] for an hour at 37 °C. Finally, chemiluminiscence was read on a plate 
reader. The results suggest that the nanopore thin-film was approximately 50 fold more 
sensitive than the corresponding non-equilibrium ELISA. When considered together with 
the simplicity of the method, label-free assay, and a very short incubation period of 60
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minutes, the nanopore thin-film sensor offers significant advantages over the ELISAs for 
biomarker measurements.
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Figure 4-12. Comparison between immunosensor assay and ELISA: (a) a typical standard 
curve of NEM in an ELISA assay [65]; (b) a typical NEM standard curve by using porous 
AAO nanosensor.
4.2.8 Blood Serum Dilution Curve
Before we tested human blood serum, we found out the minimum and the 
maximum serum volume that porous AAO sensor can detect (Figure 4-13). The serum 
volumes tested were 0.3, 0.6125,1.25, 2.5, 5,10, and 20 pi of blood serum in total buffer 
solution with volume of 50 pi. The minimum blood serum volume detected was 0.125 pi 
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Figure 4-13. Human Blood serum dilution curve. The saturation point is at 4 pi blood 
serum volume.
4.2.9 Assay Validation with Human Serum Samples
We then analyzed 10 different serum samples from 10 different patients who 
visited the urology clinic for either BPH or PC leftover from the earlier study [151]. The 
protocol for the use and analysis of the sera was approved by the Institutional Review 
Boards (IRB) at University of Louisiana at Monroe (ULM).
The freezed blood serum samples were thawed in an ice bath; then, we vortexed 
the samples and centrifuged them for 20 seconds, followed by taking 2 pi of the serum by 
using micropipette and adding it into 398 pi of PBS. The serum NEM and PSA results 
obtained by the porous AAO nanosensors were then compared with those obtained by 
NEM and PSA ELISA (Figure 4-14). Serum NEM/PSA values determined by the sensor 
were highly correlated with those determined by the ELISA (for NEM, Pearson 
Coefficient: 0.9507, for PSA, Pearson Coefficient: 0.9431). More importantly, all PC 
samples with > 4 ng/ml PSA (PSA < 4 ng/ml serum are considered non-cancer whereas 
PSA > 4 ng/ml serum are considered as potentially cancer) were also predicted to be the 
same by the current porous AAO nanosensor. Then, the NEM and PSA levels measured 
by the sensors in these samples were compared with the clinicopathological status of the
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patients (Figure 4-15). As expected, confirmed PC patients (Sample numbers #4, #6, #9) 
displayed high PSA (>4 ng/ml) as well as NEM (>4 ng/ml) levels (see Table 4-3).
Among the remaining patients, we observed some divergences between NEM and PSA 
levels. For example, patients #7 and #10 displayed 4.59 and 4.39 ng PSA/ml respectively 
(Table 4-3). Based on the current cut-off, these patients are considered as potential cancer 
patients. However, their NEM levels were low (1.762 and 2.096 ng/ml respectively) 
(Table 4-3). In contrast, patients #1 and #2 displayed normal PSA levels (2.46 and 2.20 
ng/ml respectively). However, their NEM levels were high (6.523 and 13.187 ng/ml 
respectively). Although these results are very preliminary, and a much larger number of 
patients needs to be evaluated, the results raise a possibility that NEM may detect PC 
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Figure 4-14. Comparison between porous AAO nanosensor and ELISA assay; (a) linear 
regression curve between porous AAO nanosensor vs. ELISA for NEM (Pearson 
Coefficient: 0.9507; P0.0001); (b) linear regression curve between porous AAO 
nanosensor vs. ELISA for PSA (Pearson Coefficient: 0.9431; P<0. 0001).
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Table 4-3. NEM and PSA levels in 10 different human serum samples measured by using
porous AAO sensor and ELISA.
Patient
number












1 2.46 2.73 6.52 4.73
2 2.2 2.47 13.19 12.47
3 3.21 1.15 3.54 1.15
4 5.18 13.03 4.91 6.03
5 3.28 2.57 2.39 2.57
6 31 27.6 19 27.6
7 4.59 6.66 1.76 3.66
8 3.1 2.57 1.74 3.57
9 29.13 21.3 21.03 21.3
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Figure 4-15. Analysis of NEM and PSA in serum samples of 10 urology patients as given 
in Table 4-3: Correlation between NEM and PSA in same samples (Pearson Co-efficient 
r=0.8557; p<0.0016).
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4.2.10 PC Detection Validation with Clinicopathological PC 
Confirmed Human Serum Samples
After assay validation, we analyzed the levels of NEM and PSA of 28 blood 
samples of humans who were confirmed to have the PC. The protocol for the use and 
analysis of the sera was approved by the Institutional Review Boards (IRB) at University 
of Louisiana at Monroe (ULM).
More importantly, all test results with PSA serum levels < 10 ng/ml are 
considered as a failed to detect, and all samples with NEM serum levels < 4 ng/ml are 
considered as a failed to detect as well. Any sample with serum levels more than 10 
ng/ml for PSA or 4 ng/ml for NEM is considered as a pass to detect (Table 4-5) and we 
generated a dot plot of tested PC serum samples (by using NEM and PSA biomarkers) 
with negative controls, listed in Table 4-4 (Figure 4-16). The dot plot shows that when 
we used NEM as the tested biomarker, the overlap between negative controls NEM and 
PC NEM serum levels was small. On the other hand, PSA shows higher overlap with 
negative controls. ROC curves (Figure 4-17) also showed that NEM is more sensitive 
than PSA as PC biomarkers.
The combined use of NEM as PC biomarker led to detection of 23 out of 28 PC 
cases, a success rate of 82%. On the other hand, by testing samples with PSA as PC 
biomarker, we were able to detect 19 out of 28 PC cases with a success rate of 68%.
Interestingly, three samples (4, 7, and 23) showed low NEM serum levels, but 
high PSA serum levels, and seven samples (9, 12, 13, 16, 17, 19, and 22) showed low 
PSA serum levels with high NEM serum levels. Only two samples (3, 15) gave low 
serum level readings. If we combined PSA test with NEM test, we were able to detect 26 
out of 28 PC cases (93% success).
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Table 4-4. Negative controls PSA and NEM levels measured by porous AAO nanosensor.












































Figure 4-16. Dot plot for cancer and negative controls, (a) NEM showed little overlap 
between PC samples and negative controls, (b) The overlap between PC samples and the 
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Figure 4-17. ROC curves for NEM and PSA. (a) NEM ROC curve shows that NEM 
biomarker is a specific and sensitive as PC biomarker, (b) PSA ROC curve shows that 
PSA is less specific than NEM as PC biomarker.
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1 18.967 Pass 17.053 Pass
2 5.758 Pass 10.541 Pass
3 2.129 Failed 6.310 Faded
4 2.082 Failed 17.278 Pass
5 8.755 Pass 32.548 Pass
6 9.315 Pass 22.113 Pass
7 2.449 Failed 42.770 Pass
8 10.04 Pass 10.855 Pass
9 12.461 Pass 8.247 Failed
10 7.231 Pass 12.686 Pass
11 23.926 Pass 16.771 Pass
12 14.570 Pass 6.962 Failed
13 5.982 Pass 8.115 Failed
14 17.604 Pass 10.009 Pass
15 1.432 Failed 5.061 Faded
16 6.044 Pass 3.013 Failed
17 11.738 Pass 4.249 Faded
18 11.786 Pass 16.990 Pass
19 9.612 Pass 5.953 Failed
20 12.313 Pass 12.065 Pass
21 14.495 Pass 16.398 Pass
22 10.434 Pass 5.198 Faded
23 2.245 Failed 36.750 Pass
24 6.865 Pass 15.752 Pass
25 9.087 Pass 16.586 Pass
26 23.212 Pass 17.488 Pass
27 19.205 Pass 20.252 Pass
28 13.061 Pass 13.417 Pass
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4.3 Discussion
Present results demonstrate that the porous AAO nanosensor can reliably detect 
prostate cancer biomarkers in ultra low volume of serum samples. The nanosensor offers 
several advantages over the traditional ELISAs. First, the nanosensor displayed low 
detection limits (2 pg/ml for NEM and 20 pg/ml for PSA) and the detection range for 
both markers (for NEM the range is from 2 pg/ml to 0.512 ng/ml, for PSA the range is 
from 20 pg/ml to 1 ng/ml) was 50-100-fold lower than that achieved by traditional 
ELISAs (pM to nM range) (see Figure 4-12). We could have achieved even higher 
sensitivity. Since we could detect both NEM and PSA biomarkers even in non-cancer 
individuals in as little as 0.25 pi of serum, we felt that achieving higher sensitivity will 
not provide any real benefits. The second major advantage is the technology to measure 
antibody-bound protein by optical interference signals coupled with localized surface 
plasmon resonance. This method completely eliminates the need for an enzyme-labeled 
antigen, or the requirement for efficient competition between labeled antigen and native 
molecules.
We had serious difficulties in labeling NEM peptide with an enzyme conjugate 
that was a thousand times larger than the NEM peptide. The labeled NEM was highly 
unstable, denatured rapidly, and had difficulty competing with the native protein for 
antibody binding sites, leading to unacceptably high non-specific binding. In addition, the 
technology offers several advantages, such as simplicity of the procedure, a significant 
reduction in the number of processing steps, and completion of the assay in the short time 
of fewer than two hours.
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For any new detection technique, it is critical to demonstrate that the technology 
measures the native molecules accurately, specifically, and precisely in a complex 
mixture of potentially interfering proteins normally found in biological fluids. We have 
tested the accuracy of nanosensors in multiple ways. First, we examined whether high 
protein concentrations found in biological fluids such as serum would interfere with the 
measurement of biomarkers. We found that high levels of albumin did not interfere with 
biomarker measurements.
Also, we observed that the dilution curve of the serum reached the saturation 
point at 4 pi serum volume (see Figure 4-13). Next, we added known concentrations of 
biomarkers in a serum sample, and tested whether the sensor can measure the added 
biomarker accurately. Again, the results show we could recover 76.7% to 93% of added 
antigens in a serum sample at multiple concentrations (see Table 4-2). We measured PSA 
and NEM levels in ten patient samples of PC and benign urological diseases by the 
nanosensor as well as the ELISA. The results showed that by both methods were similar 
(Figure 4-14).
Next, we examined the correlation between NEM with PSA in same samples. In 
eight out of ten specimens (except #1 and #2, which exhibited a significant diversion), we 
observed high correlation between PSA and NEM (Pearson Coefficient 0.987; p<0.0001). 
We also observed divergence between NEM and PSA in some samples. For example, 
Patients #1 and #2 displayed normal levels of PSA but elevated NEM levels. Since the 
number of cases examined is extremely low and we do not have access to the current 
status of the patients, we cannot say whether NEM can detect PCs with low PSA levels. 
However, it is a possibility since it is known that PCs with high neuroendocrine
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differentiation or metastatic PC generally display low PSA but are aggressive [160,161]. 
On the other hand, patients #7 and #10 showed borderline PSA levels (4.6 and 4.4 ng/ml 
respectively) but low NEM levels (1.76 and 2.1 ng/ml respectively).
Finally, we compared the serum PSA and NEM levels of the patients with their 
clinical diagnosis based on physical examination and pathology (Table 4-5). As expected, 
confirmed PC patients displayed high levels of both markers. Based on these 
observations, it appears that the nanosensor is reliable, accurate and precise in typical 
analytical conditions for clinical measurements.
Since PSA is known to overestimate the number of PC patients, these results 
raise a possibility that one can be more certain of cancer diagnosis when both PSA and 
NEM are elevated, rather than an increase in only one biomarker. This can significantly 
reduce the number of false positive diagnoses and, consequently, the number of biopsies 
[158,159]. Indeed, the present study is preliminary and is designed to test the validity of 
an immuno-nanosensor for the measurement of PC biomarkers. Moreover, the current 
cohort of patients is extremely small and is not sufficient to draw any clinical 
conclusions. However, these preliminary results provide a strong rationale for further 
investigation of PSA/NEM in a larger patient cohort with well-defined statistical 
objectives.
Although these studies are preliminary, they demonstrate that this novel device, 
which is fabricated by a low-cost standard micro- and nano-fabrication process [162], can 
be a viable prototype for future prostate cancer diagnostics in the clinic. The device’s low 
cost, suitability of mass production, and long shelf life can contribute to significant 
acceptability in a marketplace. Thus, considering the ease of fabrication, utilization of
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commonly available commercial components (the typical life time of the white lamp is 
1 0 0 0 0  hours), and the simplicity and sensitivity of the method make this system 
accessible to virtually any biomedical laboratory at a small cost. The fabricated sensor is 
disposable and we can fabricate more sensors when we need more.
To summarize: a novel, low-cost nanosensor has been optimized for the detection 
of two biomarker proteins (NEM and PSA) for prostate cancer. The study presents the 
preliminary proof of principle for the reliable platform for developing clinically useful 
protein detection devices that could, in the future, be translated to point-of-care in 
prostate cancer diagnostics and therapeutics.
CHAPTER 5 
CONCLUSIONS AND FUTURE WORK
5.1 Conclusions
In this dissertation, we tested different PC biomarkers (PSA and NEM) in buffer 
as well as in human serum by using optical label-free biosensor based on anodic 
aluminum oxide (AAO) nanopore thin film. Label-free biosensors provide less cost and 
didn’t affect the properties of the analyte. It is a minimally invasive method and it has no 
connection to any external compound, like fluorescent dye.
The operating principle of our porous AAO label-free biosensor is biased on 
detecting the phase difference that applied to the reflected light from the sensor surface 
due to the change of the refractive index caused by the presence of an analyte over the 
sensor surface.
Porous AAO nanosensor was fabricated by using a two-step anodization method. 
By using this method, we can control AAO pore geometry by changing anodization time 
and anodization voltage. For example, pore diameter is directly proportional to 
anodization voltage. Also, pore geometry affects the number of reflected fringes and 
fringe intensity.
Coating porous AAO nanosensor surface with gold enhanced the the fringe shape 
as well as the reflected signal intensity. Also, a gold coated nanosensor was able to make
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extraordinary contact with alkanethiols, which are the building blocks of the self­
assembled monolayer.
In this project we used porous AAO nanosensor with the following 
characteristics: Pore diameter Dp = 55 nm, pore length lp = 5 pm, pore density = 5.5 * 109 
pores per cm2, pore period = 145 nm, poricity = 34.4%, and Au coat thickness = 5 nm.
Optimizing antibody experiments were performed before we start generating 
biomarkers standerd curves. It is important to find the appropriate antibody concentration 
and to keep it constant for all experiments.
After that, we generated standered curves for NEM and PSA, and we found the 
upper and lower concentrations, detection limits for these proteins (for NEM the range is 
from 2pg/ml to 0.512 ng/ml, for PSA the range is from 20 pg/ml to 1 ng/ml). Accuracy is 
an important factor in this project; a porous AAO nanosensor was highly accurate and 
detected small changes in tested samples (as low as lpg).
Specificity experiments were performed before we started measuring biomarker 
levels in human samples. We found that porous AAO nanosensor is highly specific and 
can detect only antigens that are specific to antibody. Then we measured the lowest and 
highest voulumes of human blood serum that porous AAO nanosensor can measure; this 
nanosensor can measure the levels of PC biomarker even in very low serum volume 
(0.25pl).
Then we measured the levels of PC markers (NEM and PSA) in healthy, as well 
as PC, patients and we compared the nanopore sensor results with ELISA; the results 
showed high correlation between serum NEM and PSA values determined by the sensor 
and those by the ELISA.
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Finally, we tested the levels of PC NEM and PSA markers in pathologically 
confirmed PC patients serum. NEM detected PC in 82% of PC tested samples and PSA 
detected 6 8 % of PC tested samples. The results were promising and gave us an indication 
to improve the ability to detect PC by combining NEM with PSA test (PC detection rate 
of 93%).
5.2 Future Work
We describe the addition of a microchannel system that can be applied to AAO 
patterns (Figure 5-1). The major challenge in using a microchannel system for 
biomolecule detection is the need for multiple fluid inlets and outlets to make sure the 
different solutions do not overlap and react.
Figure 5-1. MicroChannel system fabricated over 15 AAO patterns.
The process of adding a microchannel system involves two parts: fabrication of 
the PDMS microfluidic chip and the chip assembly.
The PDMS fabrication process uses a soft lithography [163]. The fabrication 
process (Figure 5-2) starts by spinning the SU8 coat onto a silicon wafer with a diameter 
of 10 mm. The thickness of the SU8 mold will generate a cavity between the PDMS and 
AAO sensor patterns.
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Then, we will apply a mask over the SU8 mold, and we will expose UV light to 
transfer the patterns. Then we coat the mold with PDMS. After coating, the sample is 
heated at 650 for 90 minutes. After this, we will disconnect the PDMS layer from its 




Figure 5-2. PDMS microchannel system fabrication process.
After the fabrication is completed, we will attach the resulted PDMS layer to the 
patterned AAO sensor to assemble the final product (Figure 5-3). PDMS layer thickness 
should be optimized, since layer thickness affects Fabry-perot fringe shape (Figure 5-4).
PDMS
u thin film 
anopore (AAO)
Figure 5-3. Cross sectional view of the PDMS microchannel attached to gold coated (Au) 
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Figure 5-4. Not optimized PDMS layer thickness, which affects Fabry-perot fringes 
shape.
By adding microchannel system, the sensor can be developed as a smart PC 
detection system (Figure 5-5). To develop that device, disposable cartridge-type sensor, 
optical detection, electronics for wireless transmission, and control panel, a liquid-crystal 
display is needed.
Figure 5-5. Schematic of smart PC detection system with main components: disposable 
cartridge-type sensor that consists of two parts; sample preparation chip and detection 
chip, wireless communication interface to transmit patient measurement data to a clinic, 







The disposable cartridge-type sensor consists of two connected chips. One chip at 
the upstream is for biological/medical sample preparation, the other at the downstream is 
for PC screening and monitoring. Biomarker standard curve will be used as positive 
control.
The white light source is collimated by a lens and perpendicularly illuminates on 
the disposable cartridge-type sensor. A white light source, a microfluidic control network, 
a liquid-crystal display (LCD) and wireless transmission will be connected to and 
operated by a microcontroller. The battery-operated microcontroller is a one-chip unit, 
which includes CPU (central process unit), RAM, analog to digital (A/D) and digital to 
analog (D/A) converter, and interrupt controller.
The reflected signal will appear on the LCD display. Three LED lights (red, 
yellow, and green) will give us an indication if we have to increase or decrease the 
applied white light intensity to make sure that the reflected signal doesn’t reach the 
saturation level. The red LED light is going to be an indication for high intensity reflected 
signal, while the yellow light will show that the reflected signal intensity is low; the green 
light will be a mark for a suitable intensity reflected signal. The intensity of the reflected 
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hold on; plot(x2 ,y2 ,'r');hold off 
l=(length(xcorr(y 1 ,y2 ) ) - 1 )/2 ; 
figure;plot(-l:l,c,'.-');
[p,i]=findpeaks(c,'SORTSTRVdescend'); % sorting peaks in descending order 
pk_idx=j(i( 1)); % Peak Index 
shift=pk_idx*(max(x 1 )-min(x 1 ))/2048;
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